Hospital Sant Joan de Déu

Esplugues de Llobregat 8950

8 studies enrolling now · 16 studies all time

What they study most

Adolescent, Atopic Dermatitis, COVID-19, Child, Congenital Pseudarthrosis of Tibia, Crohn's Disease, Diabetes Mellitus, Type 1, Eczema, Inflammatory Bowel Diseases, Migraine, Neoplasms, Neuromuscular Diseases

Studies at this site

• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — Recruiting now
• A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer — Recruiting now
• PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease — Recruiting now
• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults — Recruiting now
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) — Recruiting now
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Recruiting now
• A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia. — Recruiting now
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Running, not enrolling
• Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients — Enrolling by invitation
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy — Running, not enrolling
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG — Running, not enrolling
• Study of Remdesivir in Participants Below 18 Years Old With COVID-19 — Completed
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes — Completed